Business
Spectral and Toray expand EAA(tm)/ PMX Theranostic to Saudi Arabia and Turkey
TORONTO, Aug. 16, 2012 /CNW/ - Spectral Diagnostics Inc., (TSX: SDI) (OTCQX: DIAGF) , a Ph...
About this update from Spectral Medical Inc
[{"type":"text","content":"\n\n\n\n\n\nTORONTO, Aug. 16, 2012 /CNW/ - Spectral Diagnostics Inc., (TSX: SDI) (OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for\n patients with septic shock, today announced an exclusive distribution\n agreement with Toray International Italy S.r.l., a subsidiary of Toray\n Industries, Inc. (Toray), to sell the Company's Endotoxin Activity\n Assay (EAA™) in combination with Toraymyxin in Saudi Arabia and Turkey.\n\n\n\"The expansion of commercial jurisdictions with Toray further confirms\n the outstanding market opportunity for this unique theranostic\n treatment for septic shock,\" said Anthony Businskas, Executive Vice\n President and CFO of Spectral. \"While our focus remains on attaining\n U.S. FDA approval for Toraymyxin in the United States, we are excited\n to develop, in collaboration with Toray, additional markets where\n patients with septic shock can benefit from our personalized medicine\n approach to treating this condition.\"\n\n\nAbout Spectral Diagnostics\nSpectral is a Phase III company seeking U.S. FDA approval for its lead\n theranostics product for the treatment of septic shock. Toraymyxin is a\n therapeutic hemoperfusion device that removes endotoxin, which can\n cause sepsis, from the bloodstream. Directed by the Company's Endotoxin\n Activity Assay (EAA™), the only FDA-cleared diagnostic for the risk of\n developing sepsis, Spectral's EUPHRATES trial is the world's first\n theranostics trial in the area of sepsis.\n\n\nToraymyxin has been approved for therapeutic use in Japan and Europe,\n and has been used safely and effectively in more than 100,000 patients\n to date. In March 2009, Spectral obtained the exclusive development and\n commercial rights in the U.S. for Toraymyxin, and in November 2010,\n signed an exclusive distribution agreement for this product in Canada.\n More than 250,000 patients are diagnosed with severe sepsis and septic\n shock in North America each year, representing a greater than $1\n billion market opportunity for Spectral. Spectral is listed on the\n Toronto Stock Exchange under the symbol SDI, and on the OTQ QX under\n the symbol DIAGF. For more information please visit www.spectraldx.com\n\n\nForward-looking statement\n\n\nInformation in this news release that is not current or historical\n factual information may constitute f...